HCA Healthcare stock faces flat 2027 earnings outlook

HCA Healthcare is entering 2027 with resilient patient demand but a largely flat preliminary earnings outlook. Becker's Hospital Review reported on October 29 that Chief Executive Sam Hazen expects earnings next year to be generally consistent with 2026, while full guidance is due with the January update.

Flat earnings meet payer pressure

Management expects service-volume growth of 2% to 3% in 2027 and expects 2026 operating results to finish in the upper half of its existing guidance ranges. The outlook is being constrained by the mix of patients behind the volume growth.

HCA said the shift from exchange coverage to uninsured care reduced third-quarter pretax income by about 400 million US dollars. Uninsured patients represented 10.5% of equivalent admissions, compared with 8.5% a year earlier, while exchange equivalent admissions fell 19% year over year. Becker's also reported that patients losing exchange coverage have been moving into uninsured status at close to a one-for-one rate.

HCA expects 550 million to 650 million US dollars less in Medicaid supplemental-payment net benefits in 2027. The comparison is affected by grandfathered state approvals that produced payments in 2026 for services delivered in earlier periods. Cost discipline, network initiatives and the company's resiliency program are intended to offset part of the pressure.

January guidance is next catalyst

HCA's longer-term growth path depends on the exchange-related payer shift easing, no material policy changes beyond HR 1 and strategic initiatives generating significant value. Until the January update, investors will focus on enrollment trends, Medicaid policy implementation and evidence that cost savings can offset weaker reimbursement economics.

HCA Healthcare stock traded at 450.00 euros on Lang & Schwarz at 16:05 CET on Tuesday, November 10, 2026.

U.S. healthcare shares remain sensitive to reimbursement policy and insurance coverage trends; broader market context is available through the S&P 500.

More news and analyses on HCA Healthcare stock.

Source: Becker's Hospital Review.